PTC Therapeutics Files 8-K Report
Ticker: PTCT · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1070081
Sentiment: neutral
Topics: 8-K, financial-reporting, disclosure
TL;DR
PTC Therapeutics filed an 8-K on 6/28/24 for standard disclosures and exhibits.
AI Summary
On June 28, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or material events were detailed in the provided text, but the filing indicates a standard reporting procedure.
Why It Matters
This 8-K filing indicates PTC Therapeutics is adhering to its reporting obligations with the SEC, providing updates on financial statements and disclosures.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- PTC THERAPEUTICS, INC. (company) — Filer
- 0001070081-24-000010 (document_id) — Accession Number
- 20240628 (date) — Report Date
- 001-35969 (company_id) — SEC File Number
- 500 Warren Corporate Center Drive (address) — Principal Executive Offices
- Warren, NJ 07059 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, and to provide a Regulation FD Disclosure.
When was this 8-K report filed?
This 8-K report was filed on June 28, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 500 Warren Corporate Center Drive, Warren, NJ 07059.
What is PTC Therapeutics, Inc.'s SEC file number?
PTC Therapeutics, Inc.'s SEC file number is 001-35969.
What is the accession number for this filing?
The accession number for this filing is 0001070081-24-000010.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-28 07:00:10
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
Filing Documents
- tmb-20240628x8k.htm (8-K) — 43KB
- tmb-20240628xex99d1.htm (EX-99.1) — 23KB
- 0001070081-24-000010.txt ( ) — 193KB
- tmb-20240628.xsd (EX-101.SCH) — 4KB
- tmb-20240628_def.xml (EX-101.DEF) — 3KB
- tmb-20240628_lab.xml (EX-101.LAB) — 16KB
- tmb-20240628_pre.xml (EX-101.PRE) — 9KB
- tmb-20240628x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 28, 2024, PTC Therapeutics, Inc. (the "Company") issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion for the renewal of the conditional marketing authorization for Translarna TM (ataluren) following the European Commission's request for re-review. The Company plans to submit a request for re-examination per European Medicines Agency guidelines. The press release is furnished as Exhibit 99.1 to this Report. The information in this Item 7.01 of this Report, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 28, 2024 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: June 28, 2024 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer